These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 21878972)
1. Joe selby. Interview by Asher Mullard. Selby J Nat Rev Drug Discov; 2011 Aug; 10(9):652. PubMed ID: 21878972 [No Abstract] [Full Text] [Related]
2. David Haslam. Interview by Asher Mullard. Haslam D Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976 [No Abstract] [Full Text] [Related]
3. Newsmaker interview: Joe Selby. Sifting medical records to determine which therapies work best. Interview by Eliot Marshall. Selby J Science; 2011 Oct; 334(6052):28. PubMed ID: 21980086 [No Abstract] [Full Text] [Related]
4. An audience with...Francis Collins. Interviewed by Asher Mullard. Collins F Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031 [No Abstract] [Full Text] [Related]
5. The evolution of the Patient-Centered Outcomes Research Institute. Manchikanti L; Helm S; Hirsch JA J Neurointerv Surg; 2012 May; 4(3):157-62. PubMed ID: 21990542 [No Abstract] [Full Text] [Related]
6. NIH encourages translational collaboration with industry. Wadman M Nat Rev Drug Discov; 2010 Apr; 9(4):255-6. PubMed ID: 20224566 [No Abstract] [Full Text] [Related]
7. Institutes in pharma cash probe. Ledford H Nature; 2008 Jun; 453(7198):963. PubMed ID: 18563109 [No Abstract] [Full Text] [Related]
8. Scripps to get less from Sandoz. Anderson C Science; 1994 May; 264(5162):1077. PubMed ID: 8178164 [No Abstract] [Full Text] [Related]
9. Terms of Scripps-Sandoz agreement may be more common than its critics believe. Mervis J Nature; 1993 Mar; 362(6417):194-5. PubMed ID: 8459840 [No Abstract] [Full Text] [Related]
10. An audience with… Henry Chesbrough. Interview by Asher Mullard. Chesbrough H Nat Rev Drug Discov; 2013 May; 12(5):338-9. PubMed ID: 23598507 [No Abstract] [Full Text] [Related]
11. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry. Dorfman HL; Reig LP Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876 [No Abstract] [Full Text] [Related]
12. Comparative effectiveness casts first shadows across US industry. Waltz E Nat Biotechnol; 2009 Mar; 27(3):211-2. PubMed ID: 19270651 [No Abstract] [Full Text] [Related]
13. Paul Brown. Interview by Asher Mullard. Brown P Nat Rev Drug Discov; 2011 Sep; 10(10):726. PubMed ID: 21959279 [No Abstract] [Full Text] [Related]
15. The NIH, research institutions and industry: working together on a shared goal. Omary MB Gastroenterology; 2007 May; 132(5):1647-50. PubMed ID: 17484859 [No Abstract] [Full Text] [Related]
16. Standards of ethics at the National Institutes of Health. Steinbrook R N Engl J Med; 2005 Mar; 352(13):1290-2. PubMed ID: 15800225 [No Abstract] [Full Text] [Related]
17. The researcher-in-chief at the Patient-Centered Outcomes Research Institute. Interview by Susan Dentzer. Selby JV Health Aff (Millwood); 2011 Dec; 30(12):2252-8. PubMed ID: 22147852 [No Abstract] [Full Text] [Related]
18. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development. Engstrom LO Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295 [No Abstract] [Full Text] [Related]
19. Paul Stoffels. Interview by Asher Mullard. Stoffels P Nat Rev Drug Discov; 2013 Apr; 12(4):258. PubMed ID: 23535929 [No Abstract] [Full Text] [Related]
20. Patient-Centered Outcomes Research Institute: the intersection of science and health care. Clancy C; Collins FS Sci Transl Med; 2010 Jun; 2(37):37cm18. PubMed ID: 20574065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]